2. Signaling Pathways
  3. Neuronal Signaling
  4. Transthyretin (TTR)

Transthyretin (TTR)

thyroxine-binding prealbumin

Transthyretin (TTR), formerly known as thyroxine-binding prealbumin, is a tetrameric protein transporting hormones in the plasma and brain. It forms a complex with retinol-binding protein (RBP), which facilitates the transport of thyroid hormones and vitamin A in the blood and cerebrospinal fluid. TTR is a positive indicator of nutrition status and is negatively correlated with inflammation. TTR is a neuroprotective and oxidative-stress-suppressing factor. The TTR structure is destabilized by mutations, oxidative modifications, aging, proteolysis, and metal cations, including Ca2+. Destabilized TTR molecules form amyloid deposits, resulting in senile and familial amyloidopathies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-177650
    Nucresiran
    		Inhibitor
    Nucresiran is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.
    Nucresiran
  • HY-153577
    WT-TTR inhibitor 1
    		Inhibitor 98.03%
    WT-TTR inhibitor 1 (Compound 21) is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM.
    WT-TTR inhibitor 1
  • HY-113950
    Dichlorophenyl-ABA
    		99.79%
    Dichlorophenyl-ABA is an inhibitor of transthyretin (TTR) amyloid fibril formation, inhibiting aggregate formation in more than 80% in TTR L55P-expressing cells.
    Dichlorophenyl-ABA
  • HY-155299
    PITB
    		Inhibitor
    PITB is a selective and orally active transthyretin (TTR) aggregation inhibitor. PITB can be used for transthyretin amyloidosis (ATTR) disease research.
    PITB
  • HY-132609A
    Patisiran sodium scrambled negative control
    Patisiran sodium scrambled negative control is the sequence scrambled negative control of Patisiran sodium.
    Patisiran sodium scrambled negative control
  • HY-159658
    TTR stabilizer 1
    		Modulator
    TTR stabilizer 1 (compound 1) is a Transthyretin (TTR) stabilizer, with an EC50 of 0.031 μM.
    TTR stabilizer 1
  • HY-132608A
    Inotersen sodium scrambled negative control
    Inotersen sodium scrambled negative control is the sequence scrambled negative control of Inotersen sodium.
    Inotersen sodium scrambled negative control
  • HY-14852S
    Tafamidis-d3
    Tafamidis-d3 is deuterium labeled Tafamidis. Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.
    Tafamidis-d<sub>3</sub>
  • HY-161505
    Transthyretin-IN-3
    		Inhibitor
    Transthyretin-IN-3 (compound 6) is a designed benzofuran analogue. Transthyretin-IN-3 selectively binds to plasma transthyretin (TTR) to inhibit Amyloid aggregation (IC50=5.0±0.2 μM). Transthyretin-IN-3 can bind to TTR's thyroxine binding site specifically by carrying chlorine substituents at specific locations in its structure. This binding can prevent TTR tetramers from dissociating into unstable monomers.
    Transthyretin-IN-3
  • HY-177650A
    Nucresiran sodium
    		Inhibitor
    Nucresiran sodium is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.
    Nucresiran sodium
  • HY-146137
    Transthyretin-IN-1
    Transthyretin-IN-1 (Compound 1d) is a transthyretin (TTR) fibril formation inhibitor. Transthyretin-IN-1 can be used for Alzheimer’s disease research.
    Transthyretin-IN-1
  • HY-P991412
    NI-301
    		Inhibitor
    NI-301 is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research.
    NI-301
  • HY-P10615
    Abz-YGGRASDQ-EDDnp
    Abz-YGGRASDQ-EDDnp is a fluorescent substrate of transthyretin (TTR) protein and is used to detect the hydrolytic activity of TTR protein.
    Abz-YGGRASDQ-EDDnp
  • HY-132590
    Revusiran
    Revusiran (ALN-TTRSC) is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran exhibits favorable nonclinical safety profiles. Revusiran can be used in studies related to transthyretin-mediated amyloidosis.
    Revusiran
  • HY-P11698
    Guanidino-G-Clamp-PNA
    		Inhibitor
    Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis.
    Guanidino-G-Clamp-PNA
  • HY-N1957R
    Gamma-Mangostin (Standard)
    		Inhibitor
    Gamma-Mangostin (Standard) is the analytical standard of Gamma-Mangostin. This product is intended for research and analytical applications. Gamma-Mangostin is a novel competitive 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist and potent epoxidase 2 (COX-2) inhibitor, as well as a transthyroxin protein (TTR) profibrosis inhibitor. Gamma-Mangostin binds to the thyroxine (T4)-binding sites and stabilized the TTR tetramer. Gamma-Mangostin inhibits [3H] spiperone binding to cultured rat aortic myocytes (IC50=3.5 nM) and reduces The perfusion pressure response of rat coronary artery to 5-HT2A (IC50=0.32 μM). Gamma-Mangostin has anti-inflammatory, antibacterial, antioxidant and anticancer activities, and can be used in the study of metabolic disorders such as diabetes.
    Gamma-Mangostin (Standard)
  • HY-107633R
    A 1120 (Standard)
    A 1120 (Standard) is the analytical standard of A 1120 (HY-107633). This product is intended for research and analytical applications. A 1120 is a high-affinity nonretinoid retinol-binding protein 4 (RBP4) antagonist with a Ki value of 8.3 nM. A 1120 disrupts the interaction between RBP4 and its binding partner transthyretin.
    A 1120 (Standard)
  • HY-176233
    Transthyretin-IN-4
    		Inhibitor
    Transthyretin-IN-4 (Compound B26) is a bivalent inhibitor of transthyretin (TTR) amyloidosis (bIC50: 0.09 µM, pIC50: 1.4 µM). Transthyretin-IN-4 is used in the study of fatal heart failure with preserved ejection fraction (HFpEF) and fatal arrhythmias.
    Transthyretin-IN-4
  • HY-160612
    Transthyretin-IN-2
    		Inhibitor
    Transthyretin-IN-2 (Compound 36) is a transthyretin (TTR) amyloidsis inhibitor, with IC50 and pIC50 values of 1.31 μM and 5.88 μM. Transthyretin-IN-2 can be used for the research of TTR amyloidosis diseases.
    Transthyretin-IN-2
  • HY-14852AR
    Tafamidis meglumine (Standard)
    Tafamidis meglumine (Standard) is the analytical standard of Tafamidis meglumine. This product is intended for research and analytical applications. Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis.
    Tafamidis meglumine (Standard)
Cat. No. Product Name / Synonyms Application Reactivity